For The Better

Last week, Recursion and Exscientia agreed to a merger that we believe is a visionary step forward in the AI-driven transformation of drug discovery. Uniting Recursion’s pioneering biological exploration capabilities with Exscientia’s AI precision chemistry, the partnership could catapult the biopharma industry into a new way of discovering and developing medicines.

Last week, Recursion and Exscientia agreed to a merger that we believe is a visionary step forward in the AI-driven transformation of drug discovery. Uniting Recursion’s pioneering biological exploration capabilities with Exscientia’s AI precision chem…

Shopify is quietly becoming a global e-commerce giant — and more.

Seniors may get a check as high as $4,873 from Social Security, but no retiree’s payment can be bigger than that in 2024. Here’s why.

This fast-growing company could turn out to be a solid long-term investment thanks to a huge end-market opportunity.

This speculative token is trading way below its record high from more than three years ago.

These companies have approved Alzheimer’s treatments that could generate billions in revenue for their respective businesses.

With the market in turmoil, long-term investors might want to pounce on these two stocks.

These consumer stocks deserve a closer look.

Technology is transforming the financial market. These companies are leading the charge.

The numbers aren’t looking so favorable as of now — and they could get even worse.

Solana continues to outperform Bitcoin this year. The reason why might surprise you.

Rocket Lab’s archrival may soon invade its home turf.

Don’t rely on just one metric to inform your investing decisions.

Alphabet has been labeled a monopoly. Now what?